Clinical trials: Adjuvant Drug Therapy
Gastric Cancer
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
Lymph node positive patients after D2 radical surgery for gastric cancer, who started to be treated at Yixing people's Hospital in April 2021, were selected and enrolled into the study group according to the patients' wishes…
- Trial name
- NCT05844371
- Testing
- tirelizumab, chemotherapy with oxaliplatin + heroda
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yixing People's Hospital
Colorectal Cancer, Relapse
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Approximately 20-50% of patients with colorectal cancer (CRC) develop distant metastasis after curative surgery, and those with early relapse within one year of completing adjuvant chemotherapy (XELOX or FOLFOX) have a…
- Trial name
- NCT07604909
- Testing
- Serplulimab, Second-Line Chemo/Targeted Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
By this clinical trial, the investigators are trying to give an answer to such a question. Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation?
- Trial name
- NCT01694576
- Testing
- Adjuvant chemotherapy with paclitaxel and nedaplatin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Carcinoma, Non-Small-Cell Lung
Sorafenib in Resected Non-small Cell Lung Carcinoma
This is an open-label, single-armed, multicentric, phase II study of Sorafenib treatment following surgery for NSCLC. The primary hypothesis is to increase the progression-free survival (PFS) of the experimental group in…
- Trial name
- SIRN (NCT00532025)
- Testing
- Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 134 people
- Sponsor
- Johannes Gutenberg University Mainz
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Breast Cancer
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.
- Trial name
- NCT00036621
- Testing
- BMS-275291
- Where
- 9 sites in United States
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
This controlled study is designed to evaluate the efficacy of TS-1 on survival compared with surgery alone. Patients will be randomly assigned to receive either surgery alone or surgery followed by treatment with TS-1 within 45…
- Trial name
- NCT00152217
- Testing
- TS-1 (S-1), Surgery
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Osteosarcoma
Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study
The study is designed to determine if the administration of multi-drug adjuvant chemotherapy for patients with primary non-metastatic osteogenic sarcoma, both prior to and after the definitive surgical procedure for their primary…
- Trial name
- NCT00001217
- Testing
- pre-surgical chemotherapy
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present.
- Trial name
- REVISE (NCT06242418)
- Testing
- FOLFOXIRI, XELOX
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small…
- Trial name
- EVIDENCE (NCT02448797)
- Testing
- Icotinib, Chemotherapy
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Breast Cancer
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00949013
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 1,600 people
- Sponsor
- SWOG Cancer Research Network
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal…
- Trial name
- NCT07643623
- Testing
- tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab, Ipilimumab N01
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Hepatocellular Carcinoma
The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
The aim of this study is to test whether the realization of 3 courses of intra-arterial chemotherapy of idarubicin-lipiodol without embolization, administered non-selectively in the hepatic artery, following the percutaneous…
- Trial name
- LIDA-ADJ (NCT04178642)
- Testing
- percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment, Percutaneous destruction of the tumor
- Where
- France
- Sponsor
- University Hospital, Montpellier
Status Asthmaticus
The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
The purpose of this investigation is to perform a pilot study assessing the safety and utility of intravenous ketamine as an adjuvant therapy in the emergency department setting for pediatric patients in acute status asthmaticus…
- Trial name
- NCT03338205
- Testing
- Ketamine
- Sponsor
- Augusta University
Triple Negative Breast Cancer
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H…
- Trial name
- NCT03562637
- Testing
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 575 people
- Sponsor
- OBI Pharma, Inc
Uterine Cervical Neoplasms, Chemoradiotherapy
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy.
- Conditions
- Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
- Trial name
- NCT05735145
- Testing
- paclitaxel combined with platinum
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
NSCLC Stage IV, NSCLC, Stage III
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Primary Objectives: To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03130829
- Testing
- Oligo Fucoidan
- Where
- 3 sites in Taiwan
- Sponsor
- Hi-Q Marine Biotech International, Ltd.
Small Bowel Adenocarcinoma, Adjuvant Chemotherapy for SBA
Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma
The utility of adjuvant chemotherapy in the management of Small Bowel Adenocarcinoma (SBA) remains unproven and awaits the results of a large, global, prospective, phase III, randomised, controlled trial.
- Trial name
- BALLAD (NCT02502370)
- Testing
- observation alone, LV5FU2, FOLFOX
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Breast Neoplasms
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor…
- Trial name
- ELEGANT (NCT02549677)
- Testing
- Epirubicin, Docetaxel, cyclophosphamide
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.